Custom protein production at quantity: specifying a batch, the release testing it needs, and securing repeat supply at the same quality

Production is the stage after a process exists: the question is no longer whether the protein can be made but how to get a defined quantity at a defined quality, repeatedly. That shifts every decision toward specification, release testing and comparability between lots, and away from the development questions that dominated earlier. This page covers how to commission a production batch and how to make the second one match the first.

the FDA cGMP rule that applies once material is destined for a drug product
Part 211
the ICH guideline on deriving and characterising cell substrates
Q5D
good laboratory practice for nonclinical studies, 21 CFR
Part 58

Figures in this panel are the rules a contract biologics service is bought and audited against, named from the regulations and guidelines themselves and linked in the sources below. They are identifiers, not prices: BioBricks publishes verified prices for synthesis services only, and does not imply a services index it has not measured.

Commissioning a batch

  1. Size the batch from consumption and stability. Order what will be used inside the material's demonstrated stability period plus a reserve, not the largest batch the unit price favours. Protein that degrades in storage is more expensive than a second batch, and stability is a property of your formulation rather than a general rule.
  2. Write a release specification. Identity, purity by a stated method, concentration by a stated method, activity where relevant, aggregate, endotoxin and appearance, each with an acceptance limit. This document is what the provider manufactures against and what an acceptance dispute is settled by.
  3. Comparability between lots. Agree what evidence shows a new lot is equivalent to the last: the same release panel plus a side-by-side test in your own assay against a retained reference. Without a reference aliquot you have no way to distinguish a lot difference from an experimental one.
  4. Formulation, storage and shipping. The buffer, the concentration, the presence of carrier protein or stabiliser, and whether the material is frozen or lyophilised all affect how it behaves on arrival. Specify them, and require a temperature record with the shipment.
  5. Secure the inputs for the repeat. The cell bank, the construct and the process description are what make the second batch possible. Establish who holds them, where the backup is, and what your rights are before the first batch rather than after.

Where production differs from development

Development asks whether the protein can be made; production asks whether it can be made the same way again. Providers that excel at the first are not automatically good at the second, and the signals differ: for production, look at batch record discipline, deviation handling and how they describe changeover.

If the material will eventually support a regulated application, ask now what would have to change and what it would cost. Retrofitting a compliant process onto a research one is substantially more work than planning for it.

Keeping a reference

Retain aliquots from every lot in your own storage, under your own control. A retained reference is the only instrument you have for answering whether a change in results came from a new lot or from something else, and it costs almost nothing.

Record which lot produced which data. Laboratories that cannot map results to lots cannot investigate a lot problem at all, which is how a supplier change becomes an unexplained drift in a dataset.

Common questions

How large a batch of custom protein should I order?
Enough for consumption within the material's demonstrated stability period plus a reserve. A larger batch at a better unit price is a false economy if the protein degrades before it is used.
What should a release specification contain?
Identity, purity and concentration each by a stated method, activity where relevant, aggregate, endotoxin where the material touches cells, and appearance, each with an acceptance limit agreed before manufacture.
How do I know a new lot matches the old one?
The same release panel, plus a side-by-side comparison against a retained aliquot of the previous lot in your own assay. Without a retained reference the comparison cannot be made.
What do I need to secure repeat supply?
Access to the cell bank, the construct and a written process description, with a backup held somewhere other than the provider's freezer. Settle this before the first batch.

Get a shortlist for your project

Free. We send a shortlist of vendors whose published prices and service scope fit what you described, built from the verified index on this site. We may email you about this enquiry and similar services from this site; opt out any time, including from the first message.

Browse by service class

Sources

Cite or embed this figure

The median advertised gene synthesis price per base pair in the US research synthesis services market was $0.11 in August 2026, across 4 verified vendor service pages recorded in BioBricks Synthesis Price Index.

Cite as: "BioBricks Synthesis Price Index", updated 2026-08-24, https://biobricks.org/custom-protein-production/.

Embed this figure (plain HTML, no scripts)
median advertised gene synthesis price per base pair · the US research synthesis services market · August 2026

$0.11

Middle 50%$0.07 – $0.15
verified vendor service pages4

Source: BioBricks Synthesis Price Index

Get a vendor shortlistCompare synthesis prices